These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38942342)

  • 1. The role of matrix metalloproteinase-9 in cardiac remodeling and dysfunction and as a possible blood biomarker in heart failure.
    Rodrigues KE; Pontes MHB; Cantão MBS; Prado AF
    Pharmacol Res; 2024 Aug; 206():107285. PubMed ID: 38942342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heart failure and role of circulating MMP-2 and MMP-9.
    Radosinska J; Barancik M; Vrbjar N
    Panminerva Med; 2017 Sep; 59(3):241-253. PubMed ID: 28399617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?
    Collier P; Watson CJ; Voon V; Phelan D; Jan A; Mak G; Martos R; Baugh JA; Ledwidge MT; McDonald KM
    Eur J Heart Fail; 2011 Oct; 13(10):1087-95. PubMed ID: 21719449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation.
    Halade GV; Jin YF; Lindsey ML
    Pharmacol Ther; 2013 Jul; 139(1):32-40. PubMed ID: 23562601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure.
    Buralli S; Dini FL; Ballo P; Conti U; Fontanive P; Duranti E; Metelli MR; Marzilli M; Taddei S
    Am J Cardiol; 2010 Mar; 105(6):853-6. PubMed ID: 20211331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of matrix metalloproteinase 9 and brain natriuretic peptide as clinical biomarkers in chronic heart failure.
    Vorovich EE; Chuai S; Li M; Averna J; Marwin V; Wolfe D; Reilly MP; Cappola TP
    Am Heart J; 2008 Jun; 155(6):992-7. PubMed ID: 18513509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of circulating matrix biomarkers to myocardial matrix metabolism in advanced heart failure.
    Kaye DM; Khammy O; Mariani J; Maeder MT
    Eur J Heart Fail; 2013 Mar; 15(3):292-8. PubMed ID: 23143794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in biomarkers in patients with heart failure with a reduced vs a preserved left ventricular ejection fraction.
    de Denus S; Lavoie J; Ducharme A; O'Meara E; Racine N; Sirois MG; Neagoe PE; Zhu L; Rouleau JL; White M
    Can J Cardiol; 2012; 28(1):62-8. PubMed ID: 22104539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temporal Patterns of 14 Blood Biomarker candidates of Cardiac Remodeling in Relation to Prognosis of Patients With Chronic Heart Failure-The Bio- SH i FT Study.
    Bouwens E; Brankovic M; Mouthaan H; Baart S; Rizopoulos D; van Boven N; Caliskan K; Manintveld O; Germans T; van Ramshorst J; Umans V; Akkerhuis KM; Kardys I
    J Am Heart Assoc; 2019 Feb; 8(4):e009555. PubMed ID: 30760105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study.
    Hansson J; Lind L; Hulthe J; Sundström J
    Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):297-303. PubMed ID: 19387352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of extracellular matrix turnover and the development of right ventricular failure after ventricular assist device implantation in patients with advanced heart failure.
    Kato TS; Chokshi A; Singh P; Khawaja T; Iwata S; Homma S; Akashi H; Cheema F; Yang J; Takayama H; Naka Y; Farr M; Mancini D; Schulze PC
    J Heart Lung Transplant; 2012 Jan; 31(1):37-45. PubMed ID: 22071239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
    George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
    Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of different Chinese medicine therapeutic methods on the ventricular remodeling and the heart function in chronic heart failure rats of Shen-yang deficiency syndrome].
    Wang J; Wu SD; Chen SC
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Sep; 32(9):1238-44. PubMed ID: 23185767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma matrix metalloproteinase-9 level is correlated with left ventricular volumes and ejection fraction in patients with heart failure.
    Yan AT; Yan RT; Spinale FG; Afzal R; Gunasinghe HR; Arnold M; Demers C; McKelvie RS; Liu PP
    J Card Fail; 2006 Sep; 12(7):514-9. PubMed ID: 16952784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing heart failure with preserved and reduced ejection fraction: An imaging and plasma biomarker approach.
    Kanagala P; Arnold JR; Singh A; Chan DCS; Cheng ASH; Khan JN; Gulsin GS; Yang J; Zhao L; Gupta P; Squire IB; Ng LL; McCann GP
    PLoS One; 2020; 15(4):e0232280. PubMed ID: 32349122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes.
    O'Meara E; Rouleau JL; White M; Roy K; Blondeau L; Ducharme A; Neagoe PE; Sirois MG; Lavoie J; Racine N; Liszkowski M; Madore F; Tardif JC; de Denus S;
    Circ Heart Fail; 2014 Sep; 7(5):773-81. PubMed ID: 25027873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma tissue inhibitor of matrix metalloproteinase-1 a predictor of long-term mortality in patients treated with cardiac resynchronization therapy.
    Trucco E; Tolosana JM; Castel MÁ; Batlle M; Borràs R; Sitges M; Guash E; Matas M; Arbelo E; Berruezo A; Brugada J; Mont L
    Europace; 2016 Feb; 18(2):232-7. PubMed ID: 25883077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction.
    Mizon-Gérard F; de Groote P; Lamblin N; Hermant X; Dallongeville J; Amouyel P; Bauters C; Helbecque N
    Eur Heart J; 2004 Apr; 25(8):688-93. PubMed ID: 15084374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-1 and -2 levels are differently regulated in acute exacerbation of heart failure in patients with and without left ventricular systolic dysfunction.
    Naito Y; Tsujino T; Lee-Kawabata M; Matsumoto M; Ezumi A; Nakao S; Goda A; Ohyanagi M; Masuyama T
    Heart Vessels; 2009 May; 24(3):181-6. PubMed ID: 19466518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.